Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease

S. Nishikawa, A. Okamura, M. Yamamori, K. Minagawa, Y. Kawamori, Y. Kawano, H. Kawano, K. Ono, Y. Katayama, M. Shimoyama, T. Matsui

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To prevent acute graft-versus-host disease (GVHD), mycophenolate mofetil (MMF) combined with calcineurin inhibitors have been used in allogeneic hematopoietic stem cell transplantation (allo-SCT). Previous studies commonly utilize MMF treatment until day 30 after allo-SCT. However, the feasibility of continuous administration after day 30 has not been well evaluated. We retrospectively assessed the safety and efficacy of extended drug administration. Twenty-five patients ceased MMF at day 30 (group A); whereas, 16 patients (group B) received extended regimens depending on individual risk factors for GVHD. No severe adverse events were observed in either group. Although the cumulative incidence (CI) of grade I to IV GVHD at day 100 was comparable between the 2 groups, the CI of grade II to IV GVHD was less among group B (12.5%) compared with group A (42.3%). Extended MMF administration may be safe and beneficial as preemptive therapy to reduce the development of moderate-to-severe acute GVHD.

Original languageEnglish (US)
Pages (from-to)3873-3876
Number of pages4
JournalTransplantation proceedings
Volume41
Issue number9
DOIs
StatePublished - Nov 1 2009

Fingerprint

Mycophenolic Acid
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Therapeutics
Incidence
Safety
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Nishikawa, S. ; Okamura, A. ; Yamamori, M. ; Minagawa, K. ; Kawamori, Y. ; Kawano, Y. ; Kawano, H. ; Ono, K. ; Katayama, Y. ; Shimoyama, M. ; Matsui, T. / Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease. In: Transplantation proceedings. 2009 ; Vol. 41, No. 9. pp. 3873-3876.
@article{6886362dffd34f419df61639a6e8e467,
title = "Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease",
abstract = "To prevent acute graft-versus-host disease (GVHD), mycophenolate mofetil (MMF) combined with calcineurin inhibitors have been used in allogeneic hematopoietic stem cell transplantation (allo-SCT). Previous studies commonly utilize MMF treatment until day 30 after allo-SCT. However, the feasibility of continuous administration after day 30 has not been well evaluated. We retrospectively assessed the safety and efficacy of extended drug administration. Twenty-five patients ceased MMF at day 30 (group A); whereas, 16 patients (group B) received extended regimens depending on individual risk factors for GVHD. No severe adverse events were observed in either group. Although the cumulative incidence (CI) of grade I to IV GVHD at day 100 was comparable between the 2 groups, the CI of grade II to IV GVHD was less among group B (12.5{\%}) compared with group A (42.3{\%}). Extended MMF administration may be safe and beneficial as preemptive therapy to reduce the development of moderate-to-severe acute GVHD.",
author = "S. Nishikawa and A. Okamura and M. Yamamori and K. Minagawa and Y. Kawamori and Y. Kawano and H. Kawano and K. Ono and Y. Katayama and M. Shimoyama and T. Matsui",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.transproceed.2009.06.231",
language = "English (US)",
volume = "41",
pages = "3873--3876",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "9",

}

Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease. / Nishikawa, S.; Okamura, A.; Yamamori, M.; Minagawa, K.; Kawamori, Y.; Kawano, Y.; Kawano, H.; Ono, K.; Katayama, Y.; Shimoyama, M.; Matsui, T.

In: Transplantation proceedings, Vol. 41, No. 9, 01.11.2009, p. 3873-3876.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease

AU - Nishikawa, S.

AU - Okamura, A.

AU - Yamamori, M.

AU - Minagawa, K.

AU - Kawamori, Y.

AU - Kawano, Y.

AU - Kawano, H.

AU - Ono, K.

AU - Katayama, Y.

AU - Shimoyama, M.

AU - Matsui, T.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - To prevent acute graft-versus-host disease (GVHD), mycophenolate mofetil (MMF) combined with calcineurin inhibitors have been used in allogeneic hematopoietic stem cell transplantation (allo-SCT). Previous studies commonly utilize MMF treatment until day 30 after allo-SCT. However, the feasibility of continuous administration after day 30 has not been well evaluated. We retrospectively assessed the safety and efficacy of extended drug administration. Twenty-five patients ceased MMF at day 30 (group A); whereas, 16 patients (group B) received extended regimens depending on individual risk factors for GVHD. No severe adverse events were observed in either group. Although the cumulative incidence (CI) of grade I to IV GVHD at day 100 was comparable between the 2 groups, the CI of grade II to IV GVHD was less among group B (12.5%) compared with group A (42.3%). Extended MMF administration may be safe and beneficial as preemptive therapy to reduce the development of moderate-to-severe acute GVHD.

AB - To prevent acute graft-versus-host disease (GVHD), mycophenolate mofetil (MMF) combined with calcineurin inhibitors have been used in allogeneic hematopoietic stem cell transplantation (allo-SCT). Previous studies commonly utilize MMF treatment until day 30 after allo-SCT. However, the feasibility of continuous administration after day 30 has not been well evaluated. We retrospectively assessed the safety and efficacy of extended drug administration. Twenty-five patients ceased MMF at day 30 (group A); whereas, 16 patients (group B) received extended regimens depending on individual risk factors for GVHD. No severe adverse events were observed in either group. Although the cumulative incidence (CI) of grade I to IV GVHD at day 100 was comparable between the 2 groups, the CI of grade II to IV GVHD was less among group B (12.5%) compared with group A (42.3%). Extended MMF administration may be safe and beneficial as preemptive therapy to reduce the development of moderate-to-severe acute GVHD.

UR - http://www.scopus.com/inward/record.url?scp=71749119355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749119355&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.06.231

DO - 10.1016/j.transproceed.2009.06.231

M3 - Article

C2 - 19917404

AN - SCOPUS:71749119355

VL - 41

SP - 3873

EP - 3876

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 9

ER -